Canada: AstraZeneca’s LOSEC Patent Valid And Infringed By Apotex

Last Updated: March 18 2015
Article by Mark Biernacki

On March 16, 2015, following a 40-day trial in 2014, Justice Barnes of the Federal Court issued a 175-page decision finding certain claims of Canadian Patent No 1,292,693 ("'693 Patent") valid and infringed by Apotex's manufacture, promotion and sale of Apo-Omeprazole capsules in Canada and elsewhere: AstraZeneca Canada Inc et al v Apotex Inc, 2015 FC 322. A separate reference will determine the quantum of Apotex's liability. This reference will be heard together with the reference to quantify AstraZeneca's liability, if any, following the finding of s. 8 liability in Apotex Inc v AstraZeneca Canada Inc, 2012 FC 559, aff'd 2013 FCA 77. One of the issues for determination will be the impact of the infringement finding on any s. 8 liability.

AstraZeneca was represented by a trial team from Smart & Biggar, comprised of Gunars Gaikis, Nancy Pei, Mark Biernacki, Lynn Ing, Junyi Chen, Urszula Wojtyra and Cameron Weir.

The decision is noteworthy for several reasons, including its unique and lengthy background, a U.S. connection and the variety of issues raised.

The '693 Patent pertains to a formulation for omeprazole (a proton pump inhibitor used for gastrointestinal disorders) having "an inert subcoating", which has been successfully marketed by AstraZeneca under the brand name LOSEC. 

The '693 Patent was first litigated by AstraZeneca and Apotex in 1993, when it became the subject of one of the earliest proceedings under the Patented Medicines (Notice of Compliance) Regulations (Court File No. T-1446-93). That case was concluded on the basis of a consent dismissal. However, the formulation disclosed by Apotex at that time turned out later to not be the one that was the subject of its regulatory submission. This led AstraZeneca to raise deceit as an issue in the later infringement action. Apotex's reliance on a different formulation also led to a judicial review application by AstraZeneca, dismissed in AstraZeneca Canada Inc v Apotex Inc, 2004 FC 1278; aff'd 2005 FCA 58.

Apotex did not separately apply a subcoating to its omeprazole pellets, but rather its subcoating was formed in situ. Thus, while there was no serious dispute that Apotex's omeprazole pellets contained a subcoating, a key issue was whether Apo-Omeprazole contained an inert subcoating as claimed in the '693 Patent.

Apotex argued that, on a purposive of construction, an "inert subcoating" covered only a subcoating that is physically applied to the pellet core and is wholly free of holes, gaps or structural anomalies. Apotex further argued that a person of skill would interpret "inert" to be a compound that is wholly unreactive with any of the other constituents of the formulation, whether or not there are any functional implications. In contrast, AstraZeneca asserted that the claimed subcoating is not limited to any particular process and need not be perfect. In rejecting Apotex's arguments, Justice Barnes cautioned against the danger of relying too heavily on the disclosure as an interpretive guide for claim language. Notably the claims at issue were not limited to any particular method of manufacture and Justice Barnes found the patentee to be entitled to protect the product regardless of the means of its creation. He also did not agree with Apotex that a person of skill would expect the subcoating to be structurally perfect and completely unreactive within its environment.

Turning to validity, Justice Barnes rejected Apotex's anticipation argument on the basis that the asserted reference (EP 495) did not disclose the use of the subcoating to overcome the stability/gastric acid resistance problem addressed by the '693 Patent. Further, in rejecting Apotex's obviousness arguments, Justice Barnes found that neither the problem faced by AstraZeneca nor its solution was as simple as Apotex suggested. He also cautioned against employing a hindsight analysis, particularly in circumstances where the expert who carries out an obviousness analysis relies on prior art references selected by counsel. He also noted that the recognition that a problem exists can be just as relevant to inventiveness as its solution. Finally, in rejecting Apotex's assertions of overbreadth, inutility and ambiguity, Justice Barnes applied the principle set forth by the Supreme Court of Canada in Burton Parsons Chemicals Inc v Hewlett-Packard (Canada) Ltd, [1976] 1 SCR 555that a patent is not overbroad because it leaves it up to the person of skill to avoid known unsuitable choices.

AstraZeneca and Apotex had already litigated the corresponding U.S. patent in respect of the same Apo-Omeprazole made by Apotex in Canada. The U.S. Court had found the U.S. patent valid and infringed. AstraZeneca relied in the Canadian action on its testing of Apo-Omeprazole in the U.S. litigation and also alleged that Apotex was estopped from disputing certain of the U.S. Court's factual findings on the characteristics of Apo-Omeprazole. AstraZeneca relied on testing of additional batches for the Canadian action.

Justice Barnes found Apotex's Apo-Omeprazole infringed the asserted claims. In so finding, Justice Barnes largely rejected Apotex's criticisms of AstraZeneca's testing expert, Dr. Martyn Davies. He also criticized the limited extent of Apotex's testing and the fact that it was not conducted by Apotex's own experts.  Further, Apotex was found to have induced infringement by its customers and by end-users throughout Canada, by promoting and selling its Apo-Omeprazole product across Canada and by directly comparing its product to LOSEC for the same indications. These findings were relevant to the determination that the applicable limitation period in this case was six years, regardless of the place where the infringing activity took place. 

Justice Barnes declined however to find foreign issue estoppel. While he noted it had "some theoretical appeal", he declined to apply the principle, inter alia, for practical considerations (it would only apply to a handful of findings and it was not necessary to fill an evidentiary gap).

As for remedies, Justice Barnes permitted AstraZeneca to elect an accounting of profits. Further, although he did not grant punitive damages for Apotex having misrepresented its Apo-Omeprazole formulation in the course of the earlier NOC proceedings, he found that the failure in not correcting the mistake at the first available opportunity may bear on the issue of costs, which has been reserved pending further submissions. 

The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Mark Biernacki
In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.